Discover and read the best of Twitter Threads about #spironolactone
Most recents (10)
1) Welcome to a 🆕#accredited #tweetorial from @cardiomet_CE! Earn 0.5hr 🆓 CE/#CME by following this 🧵. Our expert faculty is Sanjiv J Shah MD @HFpEF, Cardiologist & Director, Northwestern HFpEF Program (hfpef.org). Director of Research, @NMCardioVasc
#FOAMed
#FOAMed
1b) .@HFpEF will be sharing the algorithm he uses to treat #HFpEF based on evidence we have thus far and his anecdotal experience treating patients over the past 16 years in the @NMCardioVasc HFpEF Clinic.
#CardioTwitter #MedEd @MedTweetorials #HeartFailure
#CardioTwitter #MedEd @MedTweetorials #HeartFailure
2) CE/#CMEcredit for #physicians #physicianassociates #nurses #nursepractitioners #pharmacists 🇺🇸🇨🇦🇬🇧🇪🇺.
Statement of accreditation and faculty disclosures at cardiometabolic-ce.com/disclosures/.
FOLLOW US for accredited programs in #cardiometabolic space delivered wholly on Twitter!
Statement of accreditation and faculty disclosures at cardiometabolic-ce.com/disclosures/.
FOLLOW US for accredited programs in #cardiometabolic space delivered wholly on Twitter!
State of the art: Are #HFpEF phenotypes, a needed classification?
#Hypertension phenotype by Dr. Michele Senni
#HeartFailure2023 @lamcardio @JavedButler1 @JamalRanaMD @AHajduczok @WilfriedMullens @FH_Verbrugge @ShelleyZieroth
#Hypertension phenotype by Dr. Michele Senni
#HeartFailure2023 @lamcardio @JavedButler1 @JamalRanaMD @AHajduczok @WilfriedMullens @FH_Verbrugge @ShelleyZieroth
Has #hypertension a greater prognostic impact in HFpEF than #HFrEF?
Should we treat HTN differently in
#HFpEF patients compared to patients without HF?
What are the current evidences ?
#HeartFailure2023
Should we treat HTN differently in
#HFpEF patients compared to patients without HF?
What are the current evidences ?
#HeartFailure2023
#Spironolactone Use and Improved
Outcomes in Patients With #HFpEF With Resistant #Hypertension
#HeartFailure2023 @escardio
Outcomes in Patients With #HFpEF With Resistant #Hypertension
#HeartFailure2023 @escardio
Teaming up again with the great @VerwerftJan to share our experience with #echoCPET in #HFpEF. This hot-of-the-press paper @ESC_Journals demonstrates myriad of opportunities for diagnosis & treatment, far beyond #SGLT2i only. Tweetorial below!
@SarahStroobant2 @HerbotsLieven
@SarahStroobant2 @HerbotsLieven
We have recently described our set-up for a dedicated #dyspnoeaclinic in detail @JACCJournals
In #HFpEF, early & correct diagnosis are important, #phenotyping is everything. There are a lot of mechanisms for dyspnoea involved
In #HFpEF, early & correct diagnosis are important, #phenotyping is everything. There are a lot of mechanisms for dyspnoea involved
Current @ESC_Journals paper goes one step further: "In patients with confirmed HFpEF or probability >90% according to well-validated HFpEF scores (both are complimentary in our view), why #echoCPET within a dedicated #dyspnoea clinic? What is the impact of findings?"
1a) Welcome to one of our favorite events on the @academiccme #accredited #tweetorial feeds: a takeover of our programming from @GoggleDocs! The focus of this tweetorial is data from #ADA2022 on #SGLT2i beyond cardiac disease. Our expert author is @GoggleDocs' @drpatrickholmes.
1b) Check out our other #ADA2022 recap #tweetorial by new @GoggleDocs family member @Ines_VFonseca who focused on the cardiac data presented: ckd-ce.com/dkd13_ada22a/
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
1) Welcome to a new #accredited #tweetorial on Cardiorenal Disease in T2D & the Impact of Blocking the MR in Patients w/DKD, another CE/#CME program by one of the @GoggleDocs, this time our friend @AmarPut, Diabetes & Endocrine Consultant in the West Midlands 🇬🇧. #CaReMe #FOAMed
2) This program is supported by an educational grant from Bayer & is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com. CE/#CME credit 🇬🇧🇪🇺🇨🇦🇺🇸
3) So first – the ‘triple threat’ . . . We know of the link between the 🫀 and the kidneys and the ‘#cardiorenal’ syndrome, but what about in the setting of #diabetes?
1) Welcome to our new #accredited #tweetorial on #mechanismofaction & impact of meds commonly used in patients with or at risk for #DKD progression: #MRAs, #GLP-1 receptor agonists & #DPP-4 inhibitors. I am Sophia Ambruso DO, @sophia_kidney, from @CU_Kidney.
2) This #accredited #tweetorial series on #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. Faculty disclosures are at ckd-ce.com/disclosures/. FOLLOW US for regular programs by expert faculty!
1) Welcome to a new #accredited #tweetorial on currently available treatments for mineralocorticoid receptor (MR) antagonism (#MRA), the differences among them, and how these differences impact on treatment of cardio-reno-metabolic diseases #CaReMe #FOAMed
2) Our expert author is Dr. Patrick Holmes MB BS, MSc, DipTher, MRCGP (@drpatrickholmes), a GP Partner at St. George’s Medical Practice, Darlington for 23 years. He is a Trustee for the Primary Care Diabetes Society and is Associate Editor for Diabetic Medicine @diabeticmed.
3) This program is supported by an educational grant from Bayer & is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com. CE/#CME credit 🇬🇧🇪🇺🇨🇦🇺🇸
(1) Welcome to this #accredited #tweetorial, on recent & emerging data on finerenone, a non-steroidal mineralocorticoid receptor antagonist. We’ll discuss what it is, what evidence supports its use, & where it might fit into future #renal guidelines. I am @drkevinfernando.
(2) This program is supported by an educational grant from Bayer and is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com.
(3) Let's start with a knowledge check.
The following therapeutic options have demonstrated a significant reduction in the progression of both #CKD and #cardiovascular mortality in people living with #T2D:
1. ACEi's & ARBs
2. Spironolactone
3. SGLT2 inhibitors
4. Finerenone
The following therapeutic options have demonstrated a significant reduction in the progression of both #CKD and #cardiovascular mortality in people living with #T2D:
1. ACEi's & ARBs
2. Spironolactone
3. SGLT2 inhibitors
4. Finerenone
Don’t miss a new accredited #tweetorial launching TOMORROW here on @cardiomet_ce. #Emergencymedicine researcher and devotee of deep understanding of drug mechanism of action @md_pollack will be considering why being #nonsteroidal means better #MRA. Don't miss it! @GoggleDocs
@drkevinfernando @kidney_boy @KateIsabelle24 @SantosGallegoMD @aayshacader @VietHeartPA @Lross246 @SeguraCardio @ValleAlfonso @edgarvlermamd @nephondemand @DrRaniKhatib @HanCardiomd @SABOURETCardio @ChristosArgyrop @JavedButler1 @Steph_Achenbach @mvaduganathan #cardiotwitter
1) Welcome to a #tweetorial where we’ll explore the mechanism of action of mineralocorticoid receptor antagonists (#MRA) & consider why it's so #vogue to be #nonsteroidal. This program is accredited for 0.50 credits for #physicians #nurses #pharmacists. I am @md_pollack. #FOAMed
Current list of widely available therapeutics for #Covid_19
Added Bromhexine, Nitazoxanide, & inhaled interferon
h/t @__ice9
cc @drakchaurasia @drkrvcvijay @DrJoyeeta @drprashant86jmd
Added Bromhexine, Nitazoxanide, & inhaled interferon
h/t @__ice9
cc @drakchaurasia @drkrvcvijay @DrJoyeeta @drprashant86jmd
Commonly available drugs:
(minimum side effects)
Bromhexine+Omeprazole
Famotidine
Loperamide
VitaminsABCD+Zinc
Quercetin+Bromelain
Colchicine trial ongoing
Combine with 1 among these prescription drugs:
Doxycycline/Indomethacin/Dipyridamole/Ciclesonide
(minimum side effects)
Bromhexine+Omeprazole
Famotidine
Loperamide
VitaminsABCD+Zinc
Quercetin+Bromelain
Colchicine trial ongoing
Combine with 1 among these prescription drugs:
Doxycycline/Indomethacin/Dipyridamole/Ciclesonide
Loperamide is the odd one out here.
I put it because it is non-prescription & there is A research paper which suggests that it could disrupt the Cholesterol Synthesis Pathway
Prescription alternatives would be Fluvostatin + Losarton
I put it because it is non-prescription & there is A research paper which suggests that it could disrupt the Cholesterol Synthesis Pathway
Prescription alternatives would be Fluvostatin + Losarton
